Tag : TYPE 2 DIABETES MELLITUS

Psoriasis is a chronic inflammatory disorder characterized by systemic inflammation and elevated circulating levels of pro-inflammatory cytokines. This persistent inflammatory state has been implicated in immune-mediated injury across multiple organ systems, with particular involvement of renal tissues. However, few large-scale studies have evaluated whether psoriasis independently increases the risk of renal complications in type 2 diabetes mellitus (T2DM) patients receiving guideline-directed renoprotective therapies. A retrospective cohort study was performed by researchers in Texas to compare the risk of diabetic nephropathy, chronic kidney disease (CKD), end-stage renal disease (ESRD), and dialysis in T2DM patients with and without psoriasis who were receiving angiotensin-converting enzyme inhibitor (ACEI), angiotensin II receptor blocker (ARB) or sodium-glucose cotransporter-2 inhibitor (SGLT2i) therapies.